1427587-32-3

Usage

Uses

Since the provided materials do not offer specific applications or industries for CAS:1427587-32-3, it is not possible to list its uses or the reasons for its application in different sectors. To provide accurate information on its applications, more context and data about the compound's properties and potential uses are required.

Upstream product

• 742100-16-9 6-bromo-1-methyl-1,2,3,4-tetrahydroquinoline 
• 73183-34-3 bis(pinacol)diborane 
• 3279-90-1 6-bromo-3,4-dihydro-1H-quinolin-2-one 
• 1092523-03-9 6-bromo-1-methyl-3,4-dihydroquinolin-2(1H)-one 

Relevant academic research and scientific papers

INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN

Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.

PYRIDINONE DERIVATIVES AND THEIR USE AS SELECTIVE ALK-2 INHIBITORS

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS

The present invention is directed to imidazo[1,5-a]pyridine and imidazo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R10, R11, R12, R13, R14, R15, R16, R17 and m are as described herein, compositions including the compounds and methods of using the compounds.

NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R15, R16, R17 and n are as described herein, compositions including the compounds and methods of using the compounds.

IMIDAZOPYRAZINES AS LSD1 INHIBITORS

The present invention is directed to imidazo[1,2-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.

DIHYDROQUINOLINE-2-ONE DERIVATIVES FOR USE AS ALDOSTERONE SYNTHASE INHIBITORS

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R9, R10 and R11 are as described herein, compositions including the compounds and methods of using the compounds.

NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, R7, R8, R9, R10, R11, R12/

DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.